Elsevier

Leukemia Research

Volume 33, Issue 8, August 2009, Pages e104-e105
Leukemia Research

Letter to the Editor
Vitiligo-like lesions in an adult patient treated with Imatinib mesylate

https://doi.org/10.1016/j.leukres.2008.12.023Get rights and content

Introduction

Imatinib mesylate (Gleveec) is at present the first line treatment for CML and GIST.

The best known side effects of Imatinib mesylate are periorbital edema, fluid retention, nausea, emesis, diarrhea and myelosuppression [1]. In addition, a number of dermatological side effects have been documented, such as a pruritic maculopapular exanthema, follicular mucinosis, erythroderma, graft-versus-host-like-disease, a mycosis fungoides-like reaction, small vessels vasculitis, generalized exanthematous pustolosis, Stevens–Johnson syndrome, a pityriasis rosea-like eruption, Sweet syndrome, and a lichenoid eruption. In some cases, it can also induce local or generalized hyperpigmentation, and hair repigmentation [2], [3], [4].

We describe here a case of CML patient treated with Imatinib who developed vitiligo-like lesions.

Vitiligo is an acquired progressive disorder that results in selective disappearance of epidermal and follicular melanocytes, leaving depigmented spots of the skin, with a consequent disfigurement and possible impact on the quality of life.

Indeed, patients who have face involvement abhor having two skin colours; they may accept depigmentation of the remaining pigmented skin as a reasonable treatment, when repigmentation of involved skin is not possible.

Section snippets

Case report

A 38-year-old Caucasian man was first seen in January 2006. Physical examination showed splenomegaly and hepatomegaly. A blood count showed leukocytes of 260.930 μL−1 with the presence of myeloid precursors at various stages of differentiation in peripheral blood.

Cytogenetic and molecular analyses showed the presence of the Ph chromosome and of the hybrid bcr/abl gene. With a diagnosis of chronic myeloid leukaemia, the patient was initially treated with hydroxyurea at conventional dosage,

Discussion

Imatinib is a selective inhibitor of several tyrosine kinases: it inhibits not only the tyrosine kinase BCR-ABL, but also platelet-derived growth factor receptors (PDGFRs) and c-KIT receptor tyrosine kinases [5]. It is thought that the side effects of Imatinib treatment is due to its action on other tyrosine kinases, especially on PDGFRs and c-KIT. Indeed, mutations in the c-kit gene have been associated with hypopigmentary disorders, such as vitiligo and piebaldism [6], [7], [8], [9].

The

Conflict of interest

None.

Financial disclosure

None.

Acknowledgement

Support: none.

Contributions. All four authors contributed to in the writing and preparation of this manuscript.

References (13)

There are more references available in the full text version of this article.

Cited by (10)

  • Topical therapy for regression and melanoma prevention of congenital giant nevi

    2022, Cell
    Citation Excerpt :

    MEK- or PI3K-targeted local therapies alone or in combination may thus regress NrasQ61R-driven nevi. The c-KIT inhibitor, imatinib, has inhibitory effects on human melanocytes and infrequently causes skin hypopigmentation (Cerchione et al., 2009; Hemesath et al., 1998; Nishimura et al., 2002; Tsao et al., 2003; Wehrle-Haller, 2003; Wu et al., 2000; Yoshida et al., 2001). We found that single-drug treatment with imatinib resulted in measurable depigmentation (Figure S5K).

  • Imatinib-induced generalized vitiligo

    2022, British Journal of Haematology
  • Drug-induced hair colour changes

    2016, European Journal of Dermatology
View all citing articles on Scopus
View full text